19 assets in Lynch Syndrome

Therapeutic assets addressing Lynch Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Aspirin Lynch Syndrome	M.D. Anderson Cancer Center	P3	BB (69)
Acetylsalicylic Acid Lysinate Lynch Syndrome	Assistance Publique - Hôpitaux de Paris	P3	B (60)
Atezolizumab Lynch Syndrome	National Cancer Institute (NCI)	P3	B (60)
Fluorouracilum Lynch Syndrome	National Cancer Institute (NCI)	P3	B (60)
Naproxen Lynch Syndrome	M.D. Anderson Cancer Center	P2	B (60)
Secretin Lynch Syndrome	Johns Hopkins University	P3	B (60)
Oxaliplatin Lynch Syndrome	National Cancer Institute (NCI)	P3	B (58)
ad5 cea vaccine Lynch Syndrome	National Cancer Institute (NCI)	P2	CCC (53)
Adenovirus 5 Cea/Muc1/Brachyury Vaccine Tri-Ad5 Lynch Syndrome	National Cancer Institute (NCI)	P2	CCC (53)
Mesalamine Lynch Syndrome	Ann-Sofie Backman	P2	CCC (53)
Muc-1 Peptide Vaccine Lynch Syndrome	National Cancer Institute (NCI)	P2	CCC (53)
Nogapendekin Alfa Lynch Syndrome	National Cancer Institute (NCI)	P2	CCC (53)
Pembrolizumab Lynch Syndrome	Medicenna Therapeutics, Inc.	P1/2	CCC (52)
gad20-209-fsp, rp2d Lynch Syndrome	National Cancer Institute (NCI)	P1/2	CCC (48)
Mva-209-Fsp, Rp2D Lynch Syndrome	National Cancer Institute (NCI)	P1/2	CCC (48)
Mdna11 Lynch Syndrome	Medicenna Therapeutics, Inc.	P1/2	CC (47)
Autologous Tolerogenic Dendritic Cells Lynch Syndrome	Fundacion Clinic per a la Recerca Biomédica	P1	CC (43)
Irinotecan Lynch Syndrome	MOMA Therapeutics	P1	CC (43)
Moma-341 Lynch Syndrome	MOMA Therapeutics	P1	CC (43)